1
|
Jeha S, Crews KR, Pei D, Peyton M, Panetta JC, Ribeiro RC, Zhao X, Campbell P, Metzger ML, Yang JJ, Cheng C, Pui CH, Bhojwani D. Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies. Cancer 2021; 127:2074-2082. [PMID: 33598942 DOI: 10.1002/cncr.33465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2020] [Revised: 12/19/2020] [Accepted: 01/05/2021] [Indexed: 11/07/2022]
Abstract
BACKGROUND A phase 1 study was conducted to determine the maximum tolerated dose of bendamustine when given in combination with clofarabine, etoposide, and dexamethasone daily for 5 days in children and adolescents with relapsed or refractory hematologic malignancies. METHODS Patients younger than 22 years with second or greater relapsed or refractory acute leukemia or lymphoma after 2 or more prior regimens were eligible. With the rolling 6 design, participants received escalating doses of bendamustine (30, 40, or 60 mg/m2 /d) in combination with clofarabine (40 mg/m2 ), etoposide (100 mg/m2 ), and dexamethasone (8 mg/m2 ) daily for 5 days. Optional pharmacokinetic studies were performed in cycle 1 on day 1 and day 5. RESULTS Sixteen patients were enrolled. Six patients were treated at the dose level of 30 mg/m2 /d, 6 were treated at the dose level of 40 mg/m2 /d, and 4 were treated at the dose level of 60 mg/m2 /d. The dose-limiting toxicity was prolonged myelosuppression. The combination was otherwise well tolerated. The recommended dose of bendamustine in this combination was 30 mg/m2 /d for 5 days. Ten responses were observed after 1 cycle: 6 complete remissions, 1 durable minimal residual disease-negative complete remission without platelet recovery in a patient with early T-cell precursor leukemia, and 3 partial remissions. Six patients proceeded to transplantation. The event-free survival rate was 40.6% (95% confidence interval [CI], 17.5%-63.7%) at 1 year and 33.9% (95% CI, 11.9%-55.9%) at 3 years. CONCLUSIONS Bendamustine is well tolerated in combination with clofarabine, etoposide, and dexamethasone. The combination administered over 5 days is effective for multiple relapsed and refractory hematologic malignancies. This trial is registered with ClinicalTrials.gov (NCT01900509). LAY SUMMARY Improvements to the existing chemotherapy regimen are still needed for patients who relapse after targeted therapies and immunotherapies and for those who are not eligible for or have no access to such therapies. A regimen combining cyclophosphamide, clofarabine, and etoposide has been used in relapsed and refractory pediatric patients with hematologic malignancies. This study shows that substituting bendamustine for cyclophosphamide in combination with clofarabine and etoposide is safe and effective.
Collapse
Affiliation(s)
- Sima Jeha
- Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Kristine R Crews
- Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Deqing Pei
- Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Melissa Peyton
- Cancer Center Administration, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - John C Panetta
- Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Raul C Ribeiro
- Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Xujie Zhao
- Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Patrick Campbell
- Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Monika L Metzger
- Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Jun J Yang
- Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Cheng Cheng
- Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Ching-Hon Pui
- Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Deepa Bhojwani
- Children's Hospital Los Angeles, Los Angeles, California.,Keck School of Medicine, University of Southern California, Los Angeles, California
| |
Collapse
|
2
|
El Cheikh J, Massoud R, Haffar B, Fares E, Mahfouz R, Jisr T, Kharfan-Dabaja MA, Mougharbel A, Youssef A, Bazarbachi A, Ibrahim A. Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation. Leuk Lymphoma 2017; 58:2745-2747. [PMID: 28351183 DOI: 10.1080/10428194.2017.1307362] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Jean El Cheikh
- a Division of Hematology and Oncology, Department of Internal Medicine , American University of Beirut Medical Center , Beirut , Lebanon
| | - Radwan Massoud
- a Division of Hematology and Oncology, Department of Internal Medicine , American University of Beirut Medical Center , Beirut , Lebanon
| | - Basel Haffar
- a Division of Hematology and Oncology, Department of Internal Medicine , American University of Beirut Medical Center , Beirut , Lebanon
| | - Elie Fares
- a Division of Hematology and Oncology, Department of Internal Medicine , American University of Beirut Medical Center , Beirut , Lebanon
| | - Rami Mahfouz
- a Division of Hematology and Oncology, Department of Internal Medicine , American University of Beirut Medical Center , Beirut , Lebanon
| | - Tamima Jisr
- b Division of Hematology and Oncology , Makassed University hospital , Beirut , Lebanon
| | - Mohamed A Kharfan-Dabaja
- c Department of Blood and Marrow Transplantation , H. Lee Moffitt Cancer Center , Tampa, FL , USA
| | - Anas Mougharbel
- b Division of Hematology and Oncology , Makassed University hospital , Beirut , Lebanon
| | - Ali Youssef
- b Division of Hematology and Oncology , Makassed University hospital , Beirut , Lebanon
| | - Ali Bazarbachi
- a Division of Hematology and Oncology, Department of Internal Medicine , American University of Beirut Medical Center , Beirut , Lebanon
| | - Ahmad Ibrahim
- b Division of Hematology and Oncology , Makassed University hospital , Beirut , Lebanon
| |
Collapse
|
3
|
Gac AC, Azar N, Daguindau E, Cartron G, Fornecker LM, Gyan E, Broussais-Guillaumot F, Garidi R, Choufi B, Chantepie SP, Béné MC, Guiéze R, Bijou F, Gressin R, Amorim S, Damaj G. Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 cases. Leuk Lymphoma 2016; 57:1149-53. [PMID: 26879408 DOI: 10.3109/10428194.2016.1140160] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Bendamustine is used in the treatment of different relapsing or refractory subtypes of lymphoma. Its impact on the yield of peripheral blood stem cells is not well known. Twenty three patients who received bendamustine followed immediately or after another chemotherapy by stem cell mobilization (SCM) were included. The patients were divided into two groups: group 1 (n=17), in whom SCM was performed immediately after bendamustine chemotherapy, and group 2 (n=6), in whom SCM was performed after another cycle of chemotherapy. The success rate of mobilization after Bendamustine+/-plerixafor was 36% (eight cytapheresis succeeded for a total number of 22 cytapheresis); and 75% after other approaches (chemotherapy based or steady state) used for patients who received bendamustine previously. Although bendamustine used alone was not an effective drug to mobilize stem cells, this agent does not seem to have detrimental effects on subsequent SCM.
Collapse
Affiliation(s)
- Anne-Claire Gac
- a Institut D'hématologie De Basse Normandie, Centre Hospitalier Universitaire , Caen , France
| | - Nabih Azar
- b Service D'hématologie Clinique, Centre Hospitalier Universitaire, La Pitié Salpetrière , Paris , France
| | - Etienne Daguindau
- c ervice D'hématologie Clinique, Centre Hospitalier Universitaire, Besançon, France ; Et INSERM UMR 1098, Université De Franche-Comté , Besançon , France
| | - Guillaume Cartron
- d Département D'hématologie Clinique, Centre Hospitalier Universitaire , UMR-CNRS , Montpelliers , France
| | - Luc M Fornecker
- e Service D'hématologie Clinique, Centre Hospitalier Universitaire , Strasbourg , France
| | - Emmanuel Gyan
- f Service D'hématologie Et Thérapie Cellulaire, Centre Hospitalier Universitaire , Tours , France
| | | | - Reda Garidi
- h Service D'hématologie Clinique, Centre Hospitalier , Saint Quentin , France
| | - Bachra Choufi
- i Service D'hématologie Clinique, Centre Hospitalier , Boulogne , France
| | - Sylvain P Chantepie
- a Institut D'hématologie De Basse Normandie, Centre Hospitalier Universitaire , Caen , France
| | - Marie-Christine Béné
- j Laboratoire D'hématologie , Centre Hospitalier Universitaire , Nantes , France
| | - Romain Guiéze
- k Service D'hématologie Clinique Adulte Et De Thérapie Cellulaire CHU De Clermont-Ferrand, France; EA7283 - CREAT, Université D'auvergne , Clermont-Ferrand , France
| | - Fontanet Bijou
- l Service D'hématologie Clinique, Institut Bergonié , Bordeaux , France
| | - Remy Gressin
- m Service D'hématologie Clinique, Centre Hospitalier Universitaire , Grenoble , France
| | - Sandy Amorim
- n Service D'hématologie Clinique, Centre Hospitalier Universitaire , Saint Louis , Paris , France
| | - Gandhi Damaj
- a Institut D'hématologie De Basse Normandie, Centre Hospitalier Universitaire , Caen , France ;,o Faculté De Médecine , Université Caen-Basse Normandie , Caen , France
| |
Collapse
|
4
|
Zinzani PL, Vitolo U, Viviani S, Corradini P, Motta G, Tani M, Cascavilla N, Hohaus S, Merli F, Argnani L, Broccoli A. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2015; 15:404-8. [PMID: 25840816 DOI: 10.1016/j.clml.2015.02.023] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/16/2015] [Accepted: 02/26/2015] [Indexed: 01/12/2023]
Abstract
BACKGROUND The optimal treatment of patients with heavily pretreated Hodgkin's lymphoma is controversial. Brentuximab vedotin is an active single agent in this context. Also, bendamustine can be regarded as a safe and effective alternative for patients with relapse after autologous transplantation and as an interesting cytoreductive strategy before allogeneic transplantation. PATIENTS AND METHODS An observational, multicenter, retrospective study is reported of single-agent bendamustine in 27 heavily pretreated patients with relapsed or refractory Hodgkin's lymphoma, who had all received brentuximab vedotin as their last treatment and who showed disease progression, refractory disease, or early relapse. The primary study endpoint was the objective response rate, and the secondary endpoint was the safety of the bendamustine regimen. RESULTS The overall response rate was 55.5%, with 10 of 27 patients (37.0%) obtaining a complete response. In comparison, the overall response rate previously observed with brentuximab vedotin in the same subset of patients was much lower (18.5%). Among the 10 patients with a complete response after bendamustine, only 1 had had a complete response to brentuximab, with 2 having a partial response and 7 stable or progressive disease. With a median duration of response of 8 months, all these patients had maintained a continuous response at the last follow-up examination. The treatment was well tolerated, with rather infrequent adverse events and transient and manageable toxicities. CONCLUSION Albeit with the limits of an observational retrospective study, these data indicate that bendamustine shows its efficacy in patients already treated with brentuximab vedotin, regardless of their previously obtained response and without any significant toxicity.
Collapse
Affiliation(s)
- Pier Luigi Zinzani
- Institute of Hematology "L. e A. Seràgnoli," "Sant'Orsola-Malpighi" University Hospital, Bologna, Italy.
| | - Umberto Vitolo
- Azienda Ospedaliero-Universitaria "Città della Salute e della Scienza di Torino," Turin, Italy
| | - Simonetta Viviani
- Medical Oncology Unit 2, Department of Medical Oncology, Fondazione IRCCS "Istituto Nazionale Tumori," Milan, Italy
| | - Paolo Corradini
- Division of Hematology, Fondazione IRCCS "Istituto Nazionale Tumori," Milan, Italy
| | - Giovanna Motta
- Division of Hematology and Bone Marrow Transplant, "Vittorio Emanuele" University Hospital, Catania, Italy
| | - Monica Tani
- Hematology Unit, Department of Oncology and Hematology, "Santa Maria delle Croci" Hospital, Ravenna, Italy
| | - Nicola Cascavilla
- Division of Hematology, IRCCS "Casa Sollievo della Sofferenza," San Giovanni Rotondo, Italy
| | - Stefan Hohaus
- Institute of Hematology, "Università Cattolica del Sacro Cuore," Rome, Italy
| | - Francesco Merli
- Department of Oncology and Advanced Technologies, IRCCS "Arcispedale Santa Maria Nuova," Reggio Emilia, Italy
| | - Lisa Argnani
- Institute of Hematology "L. e A. Seràgnoli," "Sant'Orsola-Malpighi" University Hospital, Bologna, Italy
| | - Alessandro Broccoli
- Institute of Hematology "L. e A. Seràgnoli," "Sant'Orsola-Malpighi" University Hospital, Bologna, Italy
| |
Collapse
|
5
|
Sala E, Crocchiolo R, Gandolfi S, Bruno-Ventre M, Bramanti S, Peccatori J, Sarina B, Corti C, Ciceri F, Santoro A, Marktel S, Castagna L. Bendamustine Combined with Donor Lymphocytes Infusion in Hodgkin's Lymphoma Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2014; 20:1444-7. [DOI: 10.1016/j.bbmt.2014.05.024] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2014] [Accepted: 05/23/2014] [Indexed: 11/30/2022]
|
6
|
Elsoueidi R, Mulat A, Mourad H. Bendamustine treatment in a heavily pretreated Hodgkin lymphoma patient. J Oncol Pharm Pract 2014; 20:309-11. [PMID: 24847047 DOI: 10.1177/1078155214535826] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Hodgkin lymphoma is a curable disease in the vast majority of cases with a cure rate approaching 85 to 95% with initial therapy. However, some patients experience relapse and in patients with relapsed/refractory disease, prognosis remains poor and active agents are needed in this setting. Bendamustine is an alkylating agent with clinical activity against various lymphomas including follicular, mantle, diffuse large B cell lymphoma, and chronic lymphocytic leukemia; however, its activity in Hodgkin lymphoma is not yet well established. We report a case of a 55-year-old man with relapsed Hodgkin lymphoma that is heavily pretreated and was successfully treated with four cycles of single agent bendamustine (90 mg/m(2)) with complete response after two cycles and without any significant toxicity. These findings suggest that bendamustine is highly active in Hodgkin lymphoma.
Collapse
Affiliation(s)
- Raymond Elsoueidi
- Department of Hematology Oncology, Appalachian Regional Healthcare (ARH), Hazard, Kentucky, USA
| | - Alem Mulat
- Department of Pharmacy, Hazard ARH Regional Medical Center, Hazard, Kentucky, USA
| | - Hesham Mourad
- Department of Pharmacy, Hazard ARH Regional Medical Center, Hazard, Kentucky, USA
| |
Collapse
|
7
|
Derenzini E, Zinzani PL, Cheson BD. Bendamustine: role and evidence in lymphoma therapy, an overview. Leuk Lymphoma 2014; 55:1471-8. [DOI: 10.3109/10428194.2013.842986] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|